Early-stage financing and company creation models have evolved significantly over the last two decades from heavily-funded, brick & mortar, do or die entities to angel-enabled, virtual and minimalistic proof of concept start-ups with hand-selected management and externally-enabled resources and ecosystems. Indeed, the Funding Model for emerging biotech companies appears to borrow from the tech company funding models from two decades prior, including incubators and accelerators, angel investors, shared laboratory and clinical facilities, “venture engineering” and shared resource programs. At this MassBio program, under the auspices of Entrepreneurs University, we will explore the current funding models in vogue today, the investor landscape, the impact of advancing science and technology, new types of partnerships, and the novel approaches early-stage companies are executing to advance to the next stage of existence – and funding round. Finally, our panel will provide their ideas on the future of venture funding and early-stage funding models in the biotech industry, and open the program to a lively discussion with the audience. Our moderator for this program is the inimitable, ever-effervescent John Hession. Please join us.
Sponsored by the MassBio Entrepreneurs University Working group.